Cediranib

Cediranib is an oral VEGFR tyrosine kinase inhibitor that AstraZeneca developed for solid tumors then quietly shelved after withdrawing its European marketing authorisation application in 2017 despite a technically positive Phase 3 in ovarian cancer [9][11]. VEGFR is the receptor that vessel-lining cells use to grow new blood supply, and blocking it starves tumors by cutting off their vasculature. The drug now lives on almost entirely through NCI-sponsored combination trials, most prominently in pairings with the PARP inhibitor olaparib (also an AstraZeneca product) and the PD-L1 antibody durvalumab [5][6]. Recent readouts include the COPELIA Phase 2 in endometrial cancer, which met its 3-month progression-free survival endpoint for the cediranib-paclitaxel arm versus paclitaxel alone [2], and a durvalumab plus cediranib with or without olaparib Phase 2 in recurrent ovarian cancer [4]. The commercial thesis has largely collapsed: AstraZeneca has not pursued a new regulatory submission, and the drug remains investigational after nearly two decades of development [11]. What keeps academic interest alive is the mechanistic hypothesis that anti-angiogenic pressure induces functional homologous recombination deficiency (HRD, a state where cancer cells lose the ability to repair certain DNA breaks, making them vulnerable to PARP inhibitors), expanding the population that responds to PARP inhibitors beyond germline BRCA mutants [1]. NRG-GY004 confirmed a positive PFS signal in the germline BRCA-mutated subgroup even though the overall trial missed [10].

Cediranib has never been approved anywhere. AstraZeneca originally pushed it as a monotherapy antiangiogenic across ovarian, colorectal, glioblastoma, and non-small cell lung cancer, and every Phase 3 program either failed the primary endpoint, delivered a signal too weak to survive regulatory scrutiny, or was withdrawn for regulatory reasons. The ICON6 Phase 3 in platinum-sensitive relapsed ovarian cancer ("platinum-sensitive" means the disease recurred more than six months after the last platinum-based chemotherapy, indicating the tumor still responds to platinum agents) formally hit its primary progression-free survival endpoint and later reported a median overall survival benefit of roughly 7.4 months in the maintenance arm, but AstraZeneca withdrew its European marketing authorisation application in 2017, reportedly due to regulatory concerns tied to a mid-trial design change and the withdrawal was never publicly reversed [9][11]. NRG-GY004, the Phase 3 test of cediranib plus olaparib versus olaparib alone or chemotherapy in platinum-sensitive recurrent ovarian cancer, missed its progression-free survival (PFS, the time from randomization until disease worsens on imaging) primary endpoint in the overall population, though the germline BRCA-mutated subgroup showed a clinically meaningful PFS improvement (18.0 vs 12.7 months on olaparib alone) [10]. FDA has granted no breakthrough, fast track, orphan, or accelerated approval designations for cediranib in any indication. Active trials are Phase 1 and Phase 2 combination studies run by the NCI and academic sponsors, not AstraZeneca-led registrational programs [5][6][7][8]. The highest-phase active trial is Phase 2; the phase=3 status label previously carried in database systems was a legacy artifact of the completed ICON6 and NRG-GY004 programs, and has been corrected to phase=2 in this revision. No registrational readout is scheduled and no regulatory submission is in preparation.

Cediranib blocks all three VEGFR family members (VEGFR-1, 2, 3), plus PDGFR-alpha/beta and c-KIT. VEGFR-2 (encoded by the KDR gene) is the workhorse receptor for VEGF-A signaling on endothelial cells, the cells that line blood vessels. When tumors outgrow their existing vasculature they secrete VEGF to recruit new vessels, and blocking VEGFR starves that process. This mechanism is validated in the broad sense: bevacizumab, ramucirumab, and a dozen VEGFR TKIs including sorafenib, sunitinib, pazopanib, axitinib, cabozantinib, and lenvatinib are all approved. The class delivers modest survival benefits in most tumors and often fails to translate progression-free survival gains into overall survival (OS, the time from randomization to death from any cause - a stricter bar than PFS because it captures whether the drug actually extends life, not just delays radiographic progression) [3]. Cediranib's differentiator versus approved VEGFR TKIs is limited. Its potency at VEGFR-2 is comparable to axitinib and pazopanib, and its added PDGFR/KIT coverage does not appear to translate into superior efficacy in head-to-head or cross-trial comparisons. If anything, the broader kinase footprint contributes to a wider off-target toxicity profile that has required aggressive dose reductions (20 mg daily is standard in combination protocols versus initial 45 mg monotherapy exploration). The rationale for using cediranib specifically in NCI combination programs is largely historical: AstraZeneca supplied the drug alongside olaparib under a cooperative research agreement, making the pair the most tested antiangiogenic-plus-PARP combination in academic hands. There is no published mechanistic case that cediranib is superior to bevacizumab or approved TKIs for this partnering role. The more interesting biological rationale for the current cediranib program is the olaparib combination. Anti-angiogenic therapy creates tumor hypoxia, and hypoxia has been shown to downregulate expression of BRCA1, BRCA2, and RAD51, the machinery cancer cells use to repair double-strand DNA breaks. That functionally mimics BRCA loss and should expand the population sensitized to PARP inhibition beyond genetically defined HR-deficient patients [1]. The clinical execution has been mixed: NRG-GY004 did not confirm the hypothesis in the unselected front-line relapsed setting but did produce a positive PFS signal in the germline BRCA subgroup [10], leaving the HRD-positive-but-BRCA-wildtype question open.

The most concrete active readouts are academic combination studies. NCT02484404, an NCI Phase 1/2 of durvalumab plus olaparib and/or cediranib across ovarian, TNBC (triple-negative breast cancer, tumors that lack estrogen, progesterone, and HER2 receptors and therefore cannot be treated with hormonal or HER2-targeted therapies), lung, prostate, and colorectal cancer, is active at n=268 with the Phase 2 primary endpoint being objective response rate (ORR) in recurrent ovarian [5]. Recent published data from this program showed activity in a proof-of-concept cohort but the design does not support registration [4]. NCT02974621 is a randomized Phase 2 of cediranib plus olaparib versus bevacizumab in recurrent glioblastoma, n=70, primary endpoint 6-month PFS, sponsored by NCI [6]. NCT04090567 is an MD Anderson Phase 2 in germline BRCA-mutated metastatic breast cancer combining olaparib with either cediranib or ceralasertib (AZD6738, an ATR inhibitor - ATR is a kinase that senses replication stress and coordinates the DNA damage response, and blocking it makes tumors more vulnerable to DNA-damaging agents), n=60, primary endpoint ORR [7]. NCT01064648, a Phase 1/2 of cisplatin plus pemetrexed with or without cediranib in malignant pleural mesothelioma (n=117), is the trial anchored in the database record [8]. COPELIA is the most recent readout worth summarizing. The UK-run randomised Phase 2 (published in EClinicalMedicine, June 2026) enrolled patients with advanced or recurrent endometrial cancer after prior platinum chemotherapy, randomised 1:1:1 to weekly paclitaxel (control), paclitaxel plus cediranib 20 mg daily (experimental arm 1), or cediranib plus olaparib 300 mg twice daily (experimental arm 2), with the primary endpoint being the percentage of patients free from progression at 3 months. The paclitaxel-plus-cediranib arm improved 3-month PFS and RECIST response versus paclitaxel alone, and a Tie2-defined vascular responder subgroup showed a further PFS benefit (HR 0.54, 95% CI 0.33-0.88, p=0.014). The cediranib-plus-olaparib arm did not clearly outperform the paclitaxel control on the same primary endpoint. Bottom line: a Phase 2 signal for the chemotherapy combination in endometrial cancer, not the olaparib combination [2]. None of these are Phase 3 or registrational. Sample sizes are small, endpoints are activity-focused, and comparators are heterogeneous. Nothing on the current calendar produces a label.

Our model estimates a 18% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results, a randomized design, and a comparator/control arm. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Safety risk is class-typical VEGFR TKI territory: hypertension in most patients, proteinuria, hand-foot syndrome, fatigue, diarrhea, hypothyroidism, bleeding, and rare but serious GI perforations and reversible posterior leukoencephalopathy. Cediranib has been dosed at 20 mg to 45 mg daily in various regimens and consistently requires dose reductions in combination protocols [1]. Combining with olaparib compounds hematologic toxicity, anemia, neutropenia, and fatigue in particular. None of this is novel or unmanageable, but it eats into the therapeutic window relative to newer, cleaner VEGFR TKIs. Efficacy risk is the harder problem. The single-agent story is essentially closed after ICON6 and multiple Phase 3 misses [9]. The combination hypothesis with olaparib was tested in NRG-GY004 and did not deliver in the unselected platinum-sensitive population, though it did produce a real signal in the germline BRCA subgroup [10]. The remaining open question is whether an HRD-positive but BRCA-wildtype subgroup exists where the hypoxia-induced HRD synergy is real and durable. That is a narrower and lower-probability path than an unselected ovarian relapse indication. Commercial risk is severe. AstraZeneca has effectively deprioritized the asset, and any positive academic finding would need to trigger a strategic re-engagement, negotiation of manufacturing and supply, and a new regulatory package. The parallel path is off-label academic-driven use, which produces no revenue and no exclusivity for any sponsor. Composition-of-matter patents for cediranib, a compound first synthesized in the early 2000s, are likely at or near expiry (standard 20-year composition patent term); an authoritative patent-status readout was not verifiable in this pass and should be confirmed against FDA Orange Book and EPO/USPTO records before any commercial re-engagement thesis is built. If the composition patent has expired, any acquirer would need to rely on formulation, combination-use, or method-of-treatment patents to establish an exclusivity window, which is a materially weaker commercial position and a hard ceiling on any revival scenario.

Noise for now, but with a narrow window to become a signal. The commercial story is closed unless AstraZeneca re-engages, and there is no visible sign that this is happening in earnings commentary or pipeline disclosures. The scientific story is more interesting: the hypoxia-induced HRD hypothesis is testable, and the NCI-sponsored durvalumab-olaparib-cediranib combinations are the cleanest venue for that test [5]. The specific data point worth waiting for is a subgroup analysis in an HRD-positive but BRCA-wildtype ovarian cohort from NCT02484404 or a successor trial. If that signal appears with a meaningful PFS or OS delta, the drug becomes a legitimate acquisition or in-licensing target, potentially for a smaller company willing to negotiate rights from AstraZeneca - with the caveat that the exclusivity window is likely narrow given the compound's age. Catalyst calendar for monitoring: SGO Annual Meeting on Women's Cancer (the Society of Gynecologic Oncology's yearly conference where practice-changing gynecologic oncology data is often first presented) is typically in March, with SGO 2027 targeted for March 2027; ESMO Gynecological Cancers Congress runs annually, typically in June, with the next iteration expected mid-2027; ESMO Annual Congress in October also frequently carries gynecologic oncology plenary data. Also monitor AstraZeneca's oncology pipeline slide at investor days for any mention of cediranib returning to the roadmap - absence of mention is meaningful. Companies operating in adjacent PARP-plus-antiangiogenic space to watch: GSK on niraparib combinations and Merck KGaA and Pfizer on avelumab combinations. AstraZeneca's own attention on this axis has shifted to ceralasertib (the ATR inhibitor) as the preferred olaparib partner.